What is Botanix Pharmaceuticals Limited's (BOT.AX) StockRank?

MoatMap's StockRank for Botanix Pharmaceuticals Limited (BOT.AX) is 9/100, with a Strong Sell signal. This is a composite score combining Quality (29), Value (37), and Momentum (21) factor ranks across MoatMap's 20,000+ stock universe.

Does Botanix Pharmaceuticals Limited have an economic moat?

Botanix Pharmaceuticals Limited (BOT.AX) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Botanix Pharmaceuticals Limited a buy, hold, or sell?

MoatMap's current signal for Botanix Pharmaceuticals Limited (BOT.AX) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Botanix Pharmaceuticals Limited in?

Botanix Pharmaceuticals Limited (BOT.AX) operates in the Healthcare sector, specifically the Biotechnology industry (Australia).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

BOT.AX

STRONG SELL

Botanix Pharmaceuticals Limited · Healthcare · Australia · $51M · Avg Vol: $570K/d

StockRank

P/E (TTM)

—

ROE

-121.1%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

COMPANY DESCRIPTION

Botanix Pharmaceuticals Limited develops novel topical treatments for serious skin conditions, utilizing its proprietary Permeloos drug delivery technology to enhance active ingredient penetration. The company holds FDA approval for its lead product, Sofdra, making it a first-in-class topical treatment for primary axillary hyperhidrosis. It is a commercial-stage dermatology company with a patented delivery platform targeting high-value, underserved dermatological markets.

PRICE (1Y)-39.5%

SMA 50SMA 200

$0.02

RSI (14)

28.6

52W High

$0.33

From 52W High

0.1%

SCORE BREAKDOWN

Quality

ROIC

-81.0%7.6

ROE

-121.1%6.5

GP/Assets

10.4%26.8

Op. Margin

-203.7%13.9

FCF/Assets

-25.0%12.6

Piotroski

239.0

Int. Cover

-42.8x13.0

D/E Ratio

0.02x82.9

Current Ratio

2.56x47.5

Value

P/E (TTM)

—N/A

EV/EBITDA

-0.3x25.0

P/FCF

—N/A

P/B

1.0x84.7

P/S

3.2x54.0

Div Yield

—N/A

Momentum

52W High %

6%0.4

RS 6M

—N/A

SMA 50/200

0.39x0.6

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+74%64.6

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$51M

P/E (Forward)

-2.0x

Gross Margin

61.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BOT.AX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
BOT.AX	Botanix Pharmaceuticals Limited(you)	$51M	9	STRONG SELL
IMM.AX	Immutep Limited	$54M	6	STRONG SELL
ATX.AX	Amplia Therapeutics Limited	$56M	15	STRONG SELL
PTX.AX	Prescient Therapeutics Limited	$59M	17	STRONG SELL
ACW.AX	Actinogen Medical Limited	$87M	8	STRONG SELL
ILA.AX	Island Pharmaceuticals Limited	$76M	5	STRONG SELL
PAR.AX	Paradigm Biopharmaceuticals Limited	$70M	0	STRONG SELL
LTP.AX	LTR PHARMA FPO [LTP]	$71M	19	STRONG SELL
NYR.AX	Nyrada Inc.	$79M	1	STRONG SELL
DXB.AX	Dimerix Limited	$92M	1	STRONG SELL

Peer medians: ROE -19.4% · P/E 22.4x · Gross margin 49.7%

Botanix Pharmaceuticals Limited (BOT.AX) — Stock Score Summary

Botanix Pharmaceuticals Limited (BOT.AX) has a MoatMap StockRank of 9/100 based on Quality (29/100), Value (37/100), and Momentum (21/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$0.02
Market Cap	$51M
P/E (Forward)	-2.00
Price/Book	0.96
Return on Equity	-121.1%
Return on Invested Capital	-81.0%
Debt/Equity	2.00
Gross Margin	61.1%
Operating Margin	-203.7%
Revenue Growth	4271.3%
Free Cash Flow	$-23M

Botanix Pharmaceuticals Limited operates in the Biotechnology industry, part of the Healthcare sector (Australia).

Frequently Asked Questions

What is Botanix Pharmaceuticals Limited’s (BOT.AX) StockRank?: MoatMap’s StockRank for Botanix Pharmaceuticals Limited (BOT.AX) is 9/100, with a Strong Sell signal. It is a composite of Quality (29), Value (37), and Momentum (21) factor ranks across MoatMap’s 20,000+ stock universe.
Does Botanix Pharmaceuticals Limited have an economic moat?: Botanix Pharmaceuticals Limited (BOT.AX) has a Quality factor score of 29/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Botanix Pharmaceuticals Limited a buy, hold, or sell?: MoatMap’s current signal for Botanix Pharmaceuticals Limited (BOT.AX) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Botanix Pharmaceuticals Limited in?: Botanix Pharmaceuticals Limited (BOT.AX) operates in the Healthcare sector, specifically the Biotechnology industry (Australia).